Anti-Müllerian hormone: Ovarian reserve testing and its potential clinical implications

Human Reproduction Update

Volumn 20, Issue 5, 2014, Pages 688-701

  Broer, Simone L ^a   Broekmans, Frank J M ^a   Laven, Joop S E ^b   Fauser, Bart C J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anti M llerian hormone; Anti M llerian hormone assay; Menopause; Ovarian reserve testing; Polycystic ovaries

Indexed keywords

MUELLERIAN INHIBITING FACTOR;

AGE; ANOVULATION; CANCER THERAPY; CLINICAL RESEARCH; FEMALE INFERTILITY; FERTILITY; FERTILIZATION IN VITRO; HUMAN; LIFESPAN; MENOPAUSE; OVARIAN RESERVE; OVARIECTOMY; OVARY CANCER; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; PATIENT CARE; PREDICTION; PREGNANCY; PRIORITY JOURNAL; REVIEW;

ANTI-MÜLLERIAN HORMONE; ANTI-MÜLLERIAN HORMONE ASSAY; MENOPAUSE; OVARIAN RESERVE TESTING; POLYCYSTIC OVARIES;

ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; FEMALE; FERTILITY; FERTILIZATION IN VITRO; HUMANS; INFERTILITY, FEMALE; MENOPAUSE; OVARIAN FOLLICLE; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; REPRODUCTION;

EID: 84905011999     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmu020     Document Type: Review

References (150)

1. Abduljabbar M, Taheini K, Picard JY, Cate RL, Josso N. Mutations of the AMH type II receptor in two extended families with persistent Mullerian duct syndrome: lack of phenotype/genotype correlation. Horm Res Paediatr 2012;77:291-297.
2. Al Qahtani A, Muttukrishna S, Appasamy M, Johns J, Cranfield M, Visser JA, Themmen AP, Groome NP. Development of a sensitive enzyme immunoassay for anti-Mullerian hormone and the evaluation of potential clinical applications in males and females. Clin Endocrinol (Oxf) 2005;63:267-273.
3. Andersen CY, Kristensen SG, Greve T, Schmidt KT. Cryopreservation of ovarian tissue for fertility preservation in young female oncological patients. Future Oncol 2012; 8:595-608.
4. Anderson RA, Cameron DA. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 2011;96:1336-1343.
5. Anderson RA, Wallace WH. Antimullerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer. Fertil Steril 2013;99:1469-1475.
6. Anderson RA, Hindmarsh PC, Wallace WH. Induction of puberty by autograft of cryopreserved ovarian tissue in a patient previously treated for Ewing sarcoma. Eur J Cancer 2013;49:2960-2961.
7. Appt SE, Chen H, Clarkson TB, Kaplan JR. Premenopausal antimullerian hormone concentration is associated with subsequent atherosclerosis. Menopause 2012; 19:1353-1359.
8. Arbo E, Vetori DV, Jimenez MF, Freitas FM, Lemos N, Cunha-Filho JS. Serum anti-mullerian hormone levels and follicular cohort characteristics after pituitary suppression in the late luteal phase with oral contraceptive pills. Hum Reprod 2007;22:3192-3196.
9. Arce JC, La MA, Mirner KB, Nyboe AA, Fleming R. Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril 2013;99:1644-1653.
10. Belville C, Marechal JD, Pennetier S, Carmillo P, Masgrau L, Messika-Zeitoun L, Galey J, Machado G, Treton D, Gonzales J et al. Natural mutations of the anti-Mullerian hormone type II receptor found in persistent Mullerian duct syndrome affect ligand binding, signal transduction and cellular transport. Hum Mol Genet 2009; 18:3002-3013.
11. Bentzen JG, Forman JL, Johannsen TH, Pinborg A, Larsen EC, Andersen AN. Ovarian antral follicle subclasses and anti-mullerian hormone during normal reproductive aging. J Clin Endocrinol Metab 2013;98:1602-1611.
12. Berkane N, Moutafoff-Borie C. Impact of previous uterine artery embolization on fertility. Curr Opin Obstet Gynecol 2010;22:242-247.
13. Borgstrom B, Hreinsson J, Rasmussen C, Sheikhi M, Fried G, Keros V, Fridstrom M, Hovatta O. Fertility preservation in girls with turner syndrome: prognostic signs of the presence of ovarian follicles. J Clin Endocrinol Metab 2009;94:74-80.
14. Brodin T, Hadziosmanovic N, Berglund L, Olovsson M, Holte J. Antimullerian hormone levels are strongly associated with live-birth rates after assisted reproduction. J Clin Endocrinol Metab 2013;98:1107-1114.
15. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev 2009;30:465-493.
16. Broer SL, Eijkemans MJ, Scheffer GJ, van R I, de VA, Themmen AP, Laven JS, de Jong FH, te Velde ER, Fauser BC et al. Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab 2011;96:2532-2539.
17. Broer SL, Dolleman M, van DJ, Broeze KA, Opmeer BC, Bossuyt PM, Eijkemans MJ, Mol BW, Broekmans FJ. Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis. Fertil Steril 2013a;100:420-429.
18. Broer SL, van DJ, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, Eijkemans MJ, Mol BW, Broekmans FJ. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 2013b;19:26-36.
19. Brougham MF, Crofton PM, Johnson EJ, Evans N, Anderson RA, Wallace WH. Anti-Mullerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metab 2012; 97:2059-2067.
20. Buyuk E, Seifer DB, Illions E, GraziRV, Lieman H. Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with normal ovarian reserve. Fertil Steril 2011;95: 2364-2368.
21. Buzi F, Pilotta A, Dordoni D, Lombardi A, Zaglio S, Adlard P. Pelvic ultrasonography in normal girls and in girls with pubertal precocity. Acta Paediatr 1998;87:1138-1145.
22. Carmina E, Campagna AM, Mansuet P, Vitale G, Kort D, Lobo R. Does the level of serum antimullerian hormone predict ovulatory function in women with polycystic ovary syndrome with aging? Fertil Steril 2012;98:1043-1046.
23. Casadei L, Madrigale A, Puca F, Manicuti C, Emidi E, Piccione E, Dewailly D. The role of serum anti-Mullerian hormone (AMH) in the hormonal diagnosis of polycystic ovary syndrome. Gynecol Endocrinol 2013;29:545-550.
24. Crisosto N, Codner E, Maliqueo M, Echiburu B, Sanchez F, Cassorla F, Sir-PetermannT. Anti-Mullerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:2739-2743.
25. Deb S, Campbell BK, Pincott-Allen C, Clewes JS, Cumberpatch G, Raine-Fenning NJ. Quantifying effect of combined oral contraceptive pill on functional ovarian reserve as measured by serum anti-Mullerian hormone and small antral follicle count using three-dimensional ultrasound. Ultrasound Obstet Gynecol 2012; 39:574-580.
26. Dennis NA, Houghton LA, Jones GT, van Rij AM, Morgan K, McLennan IS. The level of serum anti-Mullerian hormone correlates with vitamin D status in men and women but not in boys. J Clin Endocrinol Metab 2012;97:2450-2455.
27. de Vet A, Laven JSE, de Jong FH, Themmen A, Fauser BCJM. Anti-Mullerian Hormone serum levels: A putative marker for ovarian aging. Fertil Steril 2002;77:357-362.
28. De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet 2010;376: 911-921.
29. De Vos FY, van Laarhoven HW, Laven JS, Themmen AP, Beex LV, Sweep CG, Seynaeve C, Jager A. Menopausal status and adjuvant hormonal therapy for breast cancer patients: a practical guideline. Crit Rev Oncol Hematol 2012;84:252-260.
30. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, Duhamel A, Catteau-Jonard S. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011;26:3123-3129.
31. Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ, Escobar Morreale HF. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2014;20:334-352.
32. Dillon KE, SammelMD,Prewitt M, Ginsberg JP,Walker D, Mersereau JE, GosiengfiaoY, Gracia CR. Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril 2013;99:477-483.
33. Dolleman M, Faddy MJ, van DJ, van der Schouw YT, MessowCM,Leader B, Peeters PH, McConnachie A, Nelson SM, Broekmans FJ. The relationship between anti-Mullerian hormone in women receiving fertility assessments and age at menopause in subfertile women: evidence from large population studies. J Clin Endocrinol Metab 2013a;98:1946-1953.
34. Dolleman M, Verschuren WM, Eijkemans MJ, Dolle ME, Jansen EH, Broekmans FJ, van der Schouw YT. Reproductive and lifestyle determinants of anti-Mullerian hormone in a large population-based study. J Clin Endocrinol Metab 2013b;98:2106-2115.
35. Durlinger AL, Kramer P, Karels B, de Jong FH, Uilenbroek JT, Grootegoed JA, Themmen AP. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology 1999;140:5789-5796.
36. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, Rose UM, de Jong FH, Uilenbroek JT, Grootegoed JA et al. Anti-mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001; 142:4891-4899.
37. Eilertsen TB, Vanky E, Carlsen SM. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? Hum Reprod 2012;27:2494-2502.
38. Elmashad AI. Impact of laparoscopic ovarian drilling on anti-Mullerian hormone levels and ovarian stromal blood flow using three-dimensional power Doppler in women with anovulatory polycystic ovary syndrome. Fertil Steril 2011;95:2342-6, 2346.
39. Fanchin R, Schonauer LM, Righini C, Frydman N, Frydman R, Taieb J. Serum anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation. Hum Reprod 2003;18:328-332.
40. Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 1997;18:71-106.
41. Fauser BC, Diedrich K, Devroey P. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update 2008a;14:1-14.
42. Fauser BC, Diedrich K, Devroey P. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update 2008b;14:1-14.
43. Fleming R, Nelson SM. Reproducibility of AMH. Hum Reprod 2012;27:3639-3641.
44. Fleming R, Broekmans F, Calhaz-Jorge C, Dracea L, Alexander H, Nyboe AA, Blockeel C, Jenkins J, Lunenfeld B, Platteau P et al. Can anti-Mullerian hormone concentrations be used to determine gonadotrophin dose and treatment protocol for ovarian stimulation? Reprod Biomed Online 2013;26:431-439.
45. Freeman EW, Gracia CR, Sammel MD, Lin H, Lim LC, Strauss JF III. Association of anti-mullerian hormone levels with obesity in late reproductive-age women. Fertil Steril 2007;87:101-106.
46. FreemanEW, Sammel MD, Lin H, Gracia CR. Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women. J Clin Endocrinol Metab 2012; 97:1673-1680.
47. Freour T, Mirallie S, Bach-Ngohou K, Denis M, Barriere P, Masson D. Measurement of serum anti-Mullerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART). Clin Chim Acta 2007;375:162-164.
48. Gougeon A. Caracteres qualitatifs et quantitatifs de la population folliculaire dans l'ovaire humaine adulte. Contracept Fertil Sex 1984;12:527-535.
49. Hagen CP, Aksglaede L, Sorensen K, Main KM, Boas M, Cleemann L, Holm K, Gravholt CH, Andersson AM, Pedersen AT et al. Serum levels of anti-Mullerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. J Clin Endocrinol Metab 2010; 95:5003-5010.
50. Hagen CP, Sorensen K, Anderson RA, Juul A. Serum levels of antimullerian hormone in early maturing girls before, during, and after suppression with GnRH agonist. Fertil Steril 2012a;98:1326-1330.
51. Hagen CP, Vestergaard S, Juul A, Skakkebaek NE, Andersson AM, Main KM, Hjollund NH, Ernst E, Bonde JP, Anderson RA et al. Low concentration of circulating antimullerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study. Fertil Steril 2012b; 98:1602-1608.
52. Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril 2011; 95:170-175.
53. Hehenkamp WJ, LoomanCW, Themmen AP, de Jong FH, te Velde ER, Broekmans FJ. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 2006;91:4057-4063.
54. Hendriks AE, Laven JS, Valkenburg O, Fong SL, Fauser BC, de Ridder MA, de Jong FH, Visser JA, van Ginneken AM, Boot AM, et al. Fertility and ovarian function in high-dose estrogen-treated tall women. J Clin Endocrinol Metab 2011;96:1098-1105.
55. Hendriks AE, Drop SL, Laven JS, Boot AM. Fertility of tall girls treated with high-dose estrogen, a dose-response relationship. J Clin Endocrinol Metab 2012; 97:3107-3114.
56. Hudson PL, Dougas I, Donahoe PK, Cate RL, Epstein J, Pepinsky RB, MacLaughlin DT. An immunoassay to detect human mullerian inhibiting substance in males and females during normal development. J Clin Endocrinol Metab 1990;70:16-22.
57. Hutson J, Ikawa H, Donahoe PK. The ontogeny of Mullerian inhibiting substance in the gonads of the chicken. J Pediatr Surg 1981;16:822-827.
58. Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can anti-mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab 2013;98:3332-3340.
59. Janse F, Donnez J, Anckaert E, de Jong FH, Fauser BC, Dolmans MM. Limited value of ovarian function markers following orthotopic transplantation of ovarian tissue after gonadotoxic treatment. J Clin Endocrinol Metab 2011;96:1136-1144.
60. Jeppesen JV, Anderson RA, KelseyTW,Christiansen SL, Kristensen SG, Jayaprakasan K, Raine-Fenning N, Campbell BK, Yding AC. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod 2013;19:519-527.
61. Ji J, Liu Y, Tong XH, Luo L, Ma J, Chen Z. The optimum number of oocytes in IVF treatment: an analysis of 2455 cycles in China. Hum Reprod 2013;28:2728-2734.
62. Josso N, Legeai L, Forest MG, Chaussain JL, Brauner R. An enzyme linked immunoassay for anti-mullerian hormone: a new tool for the evaluation of testicular function in infants and children. J Clin Endocrinol Metab 1990;70:23-27.
63. Josso N, Belville C, di CN, Picard JY. AMH and AMH receptor defects in persistent Mullerian duct syndrome. Hum Reprod Update 2005;11:351-356.
64. Kallio S, Aittomaki K, Piltonen T, Veijola R, Liakka A, Vaskivuo TE, Dunkel L, Tapanainen JS. Anti-Mullerian hormone as a predictor of follicular reserve in ovarian insufficiency: special emphasis on FSH-resistant ovaries. Hum Reprod 2012;27:854-860.
65. Kelsey TW, Wright P, Nelson SM, Anderson RA,Wallace WH. A validated model of serum anti-mullerian hormone from conception to menopause. PLoS One 2011; 6:e22024.
66. Kevenaar ME, Themmen AP, Rivadeneira F, Uitterlinden AG, Laven JS, van Schoor NM, Lips P, Pols HA, Visser JA. A polymorphism in the AMH type II receptor gene is associated with age at menopause in interaction with parity. Hum Reprod 2007; 22:2382-2388.
67. Klinkert ER, Broekmans FJ, Looman CW, Habbema JD, te Velde ER. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Hum Reprod 2005;20:611-615.
68. Knauff EA, Eijkemans MJ, Lambalk CB, Ten Kate-Booij MJ, Hoek A, Beerendonk CC, Laven JS, Goverde AJ, Broekmans FJ, Themmen AP et al. Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab 2009;94:786-792.
69. Krawczuk-Rybak M, Leszczynska E, Poznanska M, Zelazowska-Rutkowska B, Wysocka J. Anti-mullerian hormone as a sensitive marker of ovarian function in young cancer survivors. Int J Endocrinol 2013;2013:125080.
70. Kristensen SL, Ramlau-Hansen CH, Andersen CY, Ernst E, Olsen SF, Bonde JP, Vested A, Toft G. The association between circulating levels of antimullerian hormone and follicle number, androgens, and menstrual cycle characteristics in young women. Fertil Steril 2012;97:779-785.
71. Kumar A, Kalra B, Patel A, McDavid L, Roudebush WE. Development of a second generation anti-Mullerian hormone (AMH) ELISA. J Immunol Methods 2010; 362:51-59.
72. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update 2014; 20:124-140.
73. La Marca A, Volpe A. The Anti-Mullerian hormone and ovarian cancer. Hum Reprod Update 2007;13:265-273.
74. La Marca A, Marzotti S, Brozzetti A, Stabile G, ArtenisioAC, Bini V, Giordano R,DeBA, Volpe A, Falorni A. Primary ovarian insufficiency due to steroidogenic cell autoimmunity is associated with a preserved pool of functioning follicles. J Clin Endocrinol Metab 2009;94:3816-3823.
75. La Marca A, Nelson SM, Sighinolfi G, Manno M, Baraldi E, Roli L, Xella S, Marsella T, Tagliasacchi D, D'Amico R et al. Anti-Mullerian hormone-based prediction model for a live birth in assisted reproduction. Reprod Biomed Online 2011;4:341-349.
76. La Marca A, Papaleo E, Grisendi V, Argento C, Giulini S, Volpe A. Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles. BJOG 2012; 119:1171-1179.
77. La Marca A, Sighinolfi G, Papaleo E, Cagnacci A, Volpe A, Faddy MJ. Prediction of age at menopause from assessment of ovarian reserve may be improved by using body mass index and smoking status. PLoS One 2013;8:e57005.
78. Lane AH, Lee MM, Fuller AF Jr, Kehas DJ, Donahoe PK, MacLaughlin DT. Diagnostic utility of Mullerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Gynecol Oncol 1999;73:51-55.
79. Laven JS, Mulders AG, Visser JA, Themmen AP, de Jong FH, Fauser BC. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004;89:318-323.
80. Lawrenz B, Henes J, Henes M, Neunhoeffer E, Schmalzing M, FehmT, Kitter I. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Müllerian hormone. Lupus 2011;20:1193-1197.
81. Leader B, Hegde A, Baca Q, Stone K, Lannon B, Seifer DB, Broekmans F, Baker VL. High frequency of discordance between antimullerian hormone and follicle-stimulating hormone levels in serum from estradiol-confirmed days 2 to 4 of the menstrual cycle from 5,354 women in U.S. fertility centers. Fertil Steril 2012;98:1037-1042.
82. Lebeurrier N, Launay S, Macrez R, Maubert E, Legros H, Leclerc A, Jamin SP, Picard JY, Marret S, Laudenbach V et al. Anti-Mullerian-hormone-dependent regulation of the brain serine-protease inhibitor neuroserpin. J Cell Sci 2008;121:3357-3365.
83. Lee MM, Donahoe PK, Silverman BL, Hasegawa T, Hasegawa Y, Gustafson ML, Chang YC, MacLaughlin DT. Measurements of serum mullerian inhibiting substance in the evaluation of children with nonpalpable gonads. N Engl J Med 1997;336:1480-1486.
84. Lekamge DN, Lane M, Gilchrist RB, Tremellen KP. Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve. J Assist Reprod Genet 2008;25:515-521.
85. Li HW,Wong CY, Yeung WS, Ho PC, Ng EH. Serum anti-mullerian hormone level is not altered in women using hormonal contraceptives. Contraception 2011; 83:582-585.
86. Lie Fong S, Visser JA, Welt CK, de Rijke YB, Eijkemans MJ, Broekmans FJ, Roes EM, Peters WH, Hokken-Koelega AC, Fauser BC et al. Serum anti-mullerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab 2012;97:4650-4655.
87. Long WQ, Ranchin V, Pautier P, Belville C, Denizot P, Cailla H, Lhomme C, Picard JY, Bidart JM, Rey R. Detection of minimal levels of serum anti-Mullerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 2000; 85:540-544.
88. Luisi S, Ciani V, Podfigurna-Stopa A, Lazzeri L, De PF, Meczekalski B, Petraglia F. Serum anti-Mullerian hormone, inhibin B, and total inhibin levels in women with hypothalamic amenorrhea and anorexia nervosa. Gynecol Endocrinol 2012; 28:34-38.
89. McGee EA, Hsueh AJ. Initial and cyclic recruitment of ovarian follicles. Endocr Rev 2000; 21:200-214.
90. Merhi ZO, Seifer DB, Weedon J, Adeyemi O, Holman S, Anastos K, Golub ET, Young M, Karim R, Greenblatt R et al. Circulating vitamin D correlates with serum antimullerian hormone levels in late-reproductive-aged women: Women's Interagency HIV Study. Fertil Steril 2012;98:228-234.
91. Mulders AG, Laven JS, Eijkemans MJ, de Jong FH, Themmen AP, Fauser BC. Changes in anti-Mullerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Hum Reprod 2004; 19:2036-2042.
92. Nelson SM, La Marca A. The journey from the old to the newAMHassay: how to avoid getting lost in the values. Reprod Biomed Online 2011;23:411-420.
93. Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, Mitchell P, Ambrose P, Fleming R. Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009;24:867-875.
94. Nelson SM, Messow MC, McConnachie A, Wallace H, Kelsey T, Fleming R, Anderson RA, Leader B. External validation of nomogram for the decline in serum anti-Mullerian hormone in women: a population study of 15,834 infertility patients. Reprod Biomed Online 2011a;23:204-206.
95. Nelson SM, MessowMC,Wallace AM, Fleming R, McConnachie A. Nomogram for the decline in serum antimullerian hormone: a population study of 9,601 infertility patients. Fertil Steril 2011b;95:736-741.
96. Nielsen SN, Andersen AN, Schmidt KT, Rechnitzer C, Schmiegelow K, Bentzen JG, Larsen EC. A 10-year follow up of reproductive function in women treated for childhood cancer. Reprod Biomed Online 2013;27:192-200.
97. Olivennes F, Howles CM, Borini A, Germond M, Trew G, Wikland M, Zegers-Hochschild F, Saunders H, Alam V. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. Reprod Biomed Online 2009;18:195-204.
98. Overbeek A, Broekmans FJ, Hehenkamp WJ, Wijdeveld ME, van DJ, van Dulmen-den BE, Lambalk CB. Intra-cycle fluctuations of anti-Mullerian hormone in normal women with a regular cycle: a re-analysis. Reprod Biomed Online 2012; 24:664-669.
99. PiltonenT, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 2005;20:1820-1826.
100. Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 2009a;296:E238-E243.
101. Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 2009b;296:E238-E243.
102. Popovic-Todorovic B, Loft A, Bredkjaeer HE, Bangsboll S, Nielsen IK, Andersen AN. A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Hum Reprod 2003; 18:2275-2282.
103. Practic Committee ASRM. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril 2012;98:1407-1415.
104. Purushothaman R, Lazareva O, Oktay K, Ten S. Markers of ovarian reserve in young girls with Turner's syndrome. Fertil Steril 2010;94:1557-1559.
105. Raffi F, Metwally M, Amer S. The impact of excision of ovarian endometrioma on ovarian reserve: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012;97:3146-3154.
106. Rajpert-De Meyts E, Jorgensen N, Graem N, Muller J, Cate RL, Skakkebaek NE. Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab 1999;84:3836-3844.
107. Rustamov O, Smith A, Roberts SA, Yates AP, Fitzgerald C, Krishnan M, Nardo LG, Pemberton PW. Anti-Mullerian hormone: poor assay reproducibility in a large cohort of subjects suggests sample instability. Hum Reprod 2012;27: 3085-3091.
108. Salhi I, Cambon-Roques S, Lamarre I, Laune D, Molina F, Pugniere M, Pourquier D, Gutowski M, Picard JY, Xavier F et al. The anti-Mullerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand. Biochem J 2004;379:785-793.
109. Schipper I, Visser JA, Themmen AP, Laven JS. Limitations and pitfalls of antimullerian hormone measurements. Fertil Steril 2012;98:823-824.
110. Schuh-Huerta SM, Johnson NA, Rosen MP, Sternfeld B, Cedars MI, Reijo Pera RA.
111. Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. Hum Reprod 2012; 27:594-608.
112. Segev DL, Ha TU, Tran TT, Kenneally M, Harkin P, Jung M, MacLaughlin DT, Donahoe PK, Maheswaran S. Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway. J Biol Chem 2000; 275:28371-28379.
113. Seifer DB, Golub ET, Lambert-Messerlian G, Benning L, Anastos K, Watts DH, Cohen MH, Karim R, Young MA, Minkoff H et al. Variations in serum mullerian inhibiting substance between white, black, and Hispanic women. Fertil Steril 2009; 92:1674-1678.
114. Seifer DB, Baker VL, Leader B. Age-specific serum anti-Mullerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertil Steril 2011;95:747-750.
115. Shaw CM, Stanczyk FZ, Egleston BL, Kahle LL, Spittle CS, Godwin AK, Brinton LA, Dorgan JF. Serum antimullerian hormone in healthy premenopausal women. Fertil Steril 2011;95:2718-2721.
116. Sir-Petermann T, Marquez L, Carcamo M, Hitschfeld C, Codner E, Maliqueo M, Echiburu B, Aranda P, Crisosto N, Cassorla F. Effects of birth weight on anti-mullerian hormone serum concentrations in infant girls. J Clin Endocrinol Metab 2010;95:903-910.
117. Somunkiran A, Yavuz T, Yucel O, Ozdemir I. Anti-Mullerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2007;134:196-201.
118. Soto N, Iniguez G, Lopez P, Larenas G, Mujica V, Rey RA, Codner E. Anti-Mullerian hormone and inhibin B levels as markers of premature ovarian aging and transition to menopause in type 1 diabetes mellitus. Hum Reprod 2009;24:2838-2844.
119. Steiner AZ, Stanczyk FZ, Patel S, Edelman A. Antimullerian hormone and obesity: insights in oral contraceptive users. Contraception 2010;81:245-248.
120. Steiner AZ, Herring AH, Kesner JS, MeadowsJW, Stanczyk FZ, Hoberman S, BairdDD. Antimullerian hormone as a predictor of natural fecundability in women aged 30-42 years. Obstet Gynecol 2011;117:798-804.
121. Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum antimullerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril 2008;90:395-400.
122. Su HI, Sammel MD, Freeman EW, Lin H, DeBlasis T, Gracia CR. Body size affects measures of ovarian reserve in late reproductive age women. Menopause 2008; 15:857-861.
123. Su HI, Maas K, Sluss P, Chang RJ, Hall JE, Joffe H. The impact of depot GnRH agonist on AMH levels in healthy reproductive-aged women. J Clin Endocrinol Metab 2013; 98:E1961-6.
124. Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod 2011; 26:1768-1774.
125. te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update 2002;8:141-154.
126. Tehrani FR, Solaymani-Dodaran M, Hedayati M, Azizi F. Is polycystic ovary syndrome an exception for reproductive aging? Hum Reprod 2010;25:1775-1781.
127. Tehrani FR, Shakeri N, Solaymani-Dodaran M, Azizi F. Predicting age at menopause from serum antimullerian hormone concentration. Menopause 2011;18:766-770.
128. Teixeira J, Maheswaran S, Donahoe PK. Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr Rev 2001;22:657-674.
129. Thomson RL, Buckley JD, Moran LJ, Noakes M, Clifton PM, Norman RJ, Brinkworth GD. The effect of weight loss on anti-Mullerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum Reprod 2009;24:1976-1981.
130. Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, Dickler M, Robson M, Moy F, Goswami S et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med 2013;5:172ra21.
131. Tran ND, Cedars MI, Rosen MP. The role of anti-mullerian hormone (AMH) in assessing ovarian reserve. J Clin Endocrinol Metab 2011;96:3609-3614.
132. van Beek RD, van den Heuvel-Eibrink MM, Laven JS, de Jong FH, Themmen AP, Hakvoort-Cammel FG, van den BC, van den BH, Pieters R, de Muinck Keizer-Schrama SM. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab 2007;92:3869-3874.
133. van den Berg MH, van Dulmen-den BE, Overbeek A, Twisk JW, Schats R, van Leeuwen FE, Kaspers GJ, Lambalk CB. Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases. Hum Reprod 2010;25:1520-1527.
134. van der Gaast MH, Eijkemans MJ, van der Net JB, de Boer EJ, Burger CW, van Leeuwen FE, Fauser BC, Macklon NS. Optimum number of oocytes for a successful first IVF treatment cycle. Reprod Biomed Online 2006;13:476-480.
135. Van Disseldorp J, Lambalk CB, Kwee J, Looman CW, Eijkemans MJ, Fauser BC, Broekmans FJ. Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod 2010;25:221-227.
136. van Elburg AA, Eijkemans MJ, Kas MJ, Themmen AP, de Jong FH, van EH, Fauser BC. Predictors of recovery of ovarian function during weight gain in anorexia nervosa. Fertil Steril 2007;87:902-908.
137. van Hooff MH, AlberdaAT, Huisman GJ, Zeilmaker GH, Leerentveld RA. Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: a randomized study. Hum Reprod 1993; 8:369-373.
138. van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, Jong FH, Themmen AP. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002;17:3065-3071.
139. van Tilborg TC, Eijkemans MJ, Laven JS, Koks CA, de Bruin JP, Scheffer GJ, van Golde RJ, Fleischer K, Hoek A, Nap AW et al. The OPTIMIST study: optimisation of cost effectiveness through individualised FSH stimulation dosages for IVF treatment. A randomised controlled trial. BMC Womens Health 2012;12:29.
140. Villarroel C, Merino PM, Lopez P, Eyzaguirre FC, Van VA, Iniguez G, Codner E. Polycystic ovarian morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone. Hum Reprod 2011;26: 2861-2868.
141. Visser JA, Durlinger AL, Peters IJ, van den Heuvel ER, Rose UM, Kramer P, de Jong FH, Themmen AP. Increased oocyte degeneration and follicular atresia during the estrous cycle in anti-Mullerian hormone null mice. Endocrinology 2007; 148:2301-2308.
142. Visser JA, Hokken-Koelega AC, Zandwijken GR, Limacher A, Ranke MB, Fluck CE. Anti-Mullerian hormone levels in girls and adolescents with Turner syndrome are related to karyotype, pubertal development and growth hormone treatment. Hum Reprod 2013;28:1899-1907.
143. Wallace AM, Faye SA, Fleming R, Nelson SM. A multicentre evaluation of the new Beckman Coulter anti-Mullerian hormone immunoassay (AMH Gen II). Ann Clin Biochem 2011;48:370-373.
144. Wang J, Dicken C, Lustbader JW, Tortoriello DV. Evidence for a Mullerian-inhibiting substance autocrine/paracrine system in adult human endometrium. Fertil Steril 2009;91:1195-1203.
145. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, Kramer P, Fauser BC, Themmen AP. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10:77-83.
146. Welsh P, Smith K, Nelson SM. A single-centre evaluation of two new anti-Mullerian hormone assays and comparison with the current clinical standard assay. Hum Reprod 2014;29:1035-1041.
147. Wilson JD, George FW, Griffin JE. The hormonal control of sexual development. Science 1981;211:1278-1284.
148. Wunder DM, Bersinger NA, Yared M, Kretschmer R, Birkhauser MH. Statistically significant changes of antimullerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women. Fertil Steril 2008;89: 927-933.
149. Yates AP, Rustamov O, Roberts SA, Lim HY, Pemberton PW, Smith A, Nardo LG. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum Reprod 2011;26:2353-2362.
150. Zuvela E,Walls M, Matson P. Within-laboratory and between-laboratory variability in the measurement of anti-mullerian hormone determined within an external quality assurance scheme. Reprod Biol 2013;13:255-257.